Payment overview · 2025
General Payments
$1,273.11
71 reported records · 22 companies
Healthcare provider profile · identity verified
Miguel Pablo Rivera, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · METAIRIE, LA · NPI 1104840404
Verified facts
What the public records show
CMS Open Payments records show Miguel Pablo Rivera, M.D. received $1,273.11 in general payments during 2025 across 71 reported records.
Antares Pharma, Inc. accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 418 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 312 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $180.11 | 14.2% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $152.20 | 11.9% | 9 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $145.50 | 11.4% | 11 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $95.48 | 7.5% | 5 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $91.44 | 7.2% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $84.01 | 6.6% | 4 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $73.80 | 5.8% | 5 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $54.45 | 4.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.14 | 3.8% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.93 | 3.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.73 | 3.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.57 | 2.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $35.39 | 2.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$33.51 | 2.6% | 2 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $28.65 | 2.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.74 | 1.6% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.34 | 1.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $19.14 | 1.5% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $18.42 | 1.4% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.28 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.68 | 1.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.60 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,273.11 | 71 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $180.11 | 10 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $132.16 | 10 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $95.48 | 5 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $91.44 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $84.50 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $84.30 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $84.01 | 4 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $73.80 | 5 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $73.80 | 5 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $73.80 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $65.53 | 4 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $54.45 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $48.14 | 2 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $44.93 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $40.73 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.57 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $35.39 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $28.65 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| PROPEL Normalized: propel |
Device | Medtronic, Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $13.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 109 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 418 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 312 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
221 | 50 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
418 | 71 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
70 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
312 | 59 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1015 | 269 |
| Mounjaro | Tirzepatide | 418 | 71 |
| Metformin Hcl Er | Metformin Hcl | 391 | 122 |
| Ozempic | Semaglutide | 312 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 286 | 91 |
| Alprazolam | Alprazolam | 274 | 44 |
| Glimepiride | Glimepiride | 246 | 74 |
| Synthroid | Levothyroxine Sodium | 221 | 50 |
| Gabapentin | Gabapentin | 218 | 67 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 214 | 54 |
| Metformin Hcl | Metformin Hcl | 202 | 61 |
| Pravastatin Sodium | Pravastatin Sodium | 198 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 187 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 187 | 64 |
| Losartan Potassium | Losartan Potassium | 175 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 48 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 158 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 150 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 137 | 43 |
| Testosterone Cypionate | Testosterone Cypionate | 131 | 27 |
| Novolog Flexpen | Insulin Aspart | 127 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 124 | 43 |
| Ezetimibe | Ezetimibe | 122 | 39 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 111 | 37 |
| Jardiance | Empagliflozin | 109 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 104 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 27 |
| Tramadol Hcl | Tramadol Hcl | 103 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 16 |
| Potassium Chloride | Potassium Chloride | 97 | 22 |
| Liothyronine Sodium | Liothyronine Sodium | 88 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 24 |
| Trazodone Hcl | Trazodone Hcl | 82 | 25 |
| Glipizide Er | Glipizide | 77 | 30 |
| Trulicity | Dulaglutide | 70 | 12 |
| Furosemide | Furosemide | 69 | 24 |
| Allopurinol | Allopurinol | 67 | 15 |
| Omeprazole | Omeprazole | 67 | 19 |
| Cinacalcet Hcl | Cinacalcet Hcl | 66 | 11 |
| Armour Thyroid | Thyroid,pork | 64 | 15 |
| Lisinopril | Lisinopril | 64 | 20 |
| Finasteride | Finasteride | 61 | 23 |
| Humalog Kwikpen U-100 | Insulin Lispro | 60 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 20 |
| Eliquis | Apixaban | 59 | 12 |
| Meloxicam | Meloxicam | 57 | 23 |
| Methimazole | Methimazole | 57 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 16 |
| Januvia | Sitagliptin Phosphate | 54 | 11 |
| Simvastatin | Simvastatin | 54 | 20 |
| Montelukast Sodium | Montelukast Sodium | 49 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 49 | 23 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 47 | 14 |
| Donepezil Hcl | Donepezil Hcl | 44 | suppressed |
| Anastrozole | Anastrozole | 43 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 34 |
| Farxiga | Dapagliflozin Propanediol | 42 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 24 |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | suppressed |
| Irbesartan | Irbesartan | 40 | 12 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 38 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 34 | 11 |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 32 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 17 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 13 |
| Novolog | Insulin Aspart | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | 14 |
| Famotidine | Famotidine | 23 | 12 |
| Carvedilol | Carvedilol | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 20 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 20 | suppressed |
| Nateglinide | Nateglinide | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 15 |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Glyburide | Glyburide | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Victoza 3-Pak | Liraglutide | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,273.11 · 71 records | Antares Pharma, Inc. | AZMIRO, Dexcom G6 Transmitter, GVOKE HYPOPEN, JARDIANCE, JATENZO, Kerendia, Korlym, MINIMED 780G, MOUNJARO, NP Thyroid 60, Omnipod, Ozempic, PROPEL, RECORLEV, Rybelsus, STRENSIQ, TEPEZZA, TWIIST, TZIELD, UBRELVY, UNITHROID, Veozah, XYOSTED, Yorvipath, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error